Drug Trial Radar · NCT04547166
A Clinical Study to Evaluate Efficacy and Safety of Serplulimab(HLX10) Combined With Bevacizumab(HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)
Last checked: Nov 19, 2026Latest source record: Oct 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
568
Planned (sponsor's estimate)
Start
Mar 10, 2021
Primary completion
Sep 24, 2025
Study completion Dec 30, 2026
Sponsor
- Lead sponsor
- Shanghai Henlius BiotechIndustry
- Sponsor type
- Industry
- First posted
- Sep 14, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a two-arm, randomized, double-blinded, multicenter phase III clinical study to evaluate the clinical efficacy of Serplulimab (HLX10) in Combination With Bevacizumab and Chemotherapy (XELOX) Versus Placebo in Combination With Bevacizumab and Chemotherapy (XELOX) in First-line Treatment of Patients With Metastatic Colorectal Cancer (mCRC)
Conditions
- Metastatic Colorectal Cancer
Interventions
HLX10Drug
a single fixed dose of 300 mg, intravenous infusion (IV), every 3 weeks (Day 1 of each cycle \[D1\]), non-reducible.
HLX04、Drug
7.5mg/kg, IV, every 3 weeks (D1 of each cycle), non-reducible.
Primary outcomes
What the sponsor says the trial is designed to measure.
- PFSTime frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Locations
5 sites in 2 countries. Site status is shown where the registry gives one.
Linyi Cancer Hospital
Linyi, China · Recruiting
Fudan University Affiliated Oncology Hospital
Shanghai, China · Recruiting
Center for Cancer Prevention and Treatment of Sun Yat-sen University
Guangzhou, Guangdong, China · Recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Recruiting
National Cancer Center
Kashiwa, Japan · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.